RS represents a major unmet need in the lymphoma field, being refractory to standard and intensified chemoimmunotherapy approaches normally used for DLBCL and to novel CLL-targeted agents [Bruton tyrosine kinase (BTK) and BCL-2 inhibitors (BCL-2i) [3,4]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.